Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  McCaughey, Laura C ^a,b,c   Ritchie, Neil D ^a   Douce, Gillian R ^a   Evans, Thomas J ^a   Walker, Daniel ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIOCIN; PYOCIN; TOBRAMYCIN;

ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; LUNG; LUNG DISEASE; MICROBIOLOGY; MOUSE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPECIES DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; DISEASE MODELS, ANIMAL; FEMALE; LUNG; LUNG DISEASES; MICE; MICE, INBRED C57BL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYOCINS; SPECIES SPECIFICITY; TOBRAMYCIN;

EID: 84979243371     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30201     Document Type: Article

References (41)

1. Souli, M., Galani, I., Giamarellou, H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Eur. Surveil. 13 (2008).
2. Vila, J., Luis Martinez, J. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors. Curr. Drug Targets. 9, 797-807 (2008).
3. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Bio. Rev. 67, 593-656 (2003).
4. Flamm, R. K. et al. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48, 2431-2436 (2004).
5. Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34, 634-640 (2002).
6. Drenkard, E., Ausubel, F. M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature. 416, 740-743 (2002).
7. Mah, T. F. et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 426, 306-310 (2003).
8. Farrell, D. J., Flamm, R. K., Sader, H. S., Jones, R. N. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob. Agents Chemother. 57, 6305-6310 (2013).
9. Shlaes, D. M., Sahm, D., Opiela, C., Spellbergc, B. The FDA reboot of antibiotic development. Antimicrob. Agents Chemother. 57, 4605-4607 (2013).
10. Bumann, D. Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 11, 387-392 (2008).
11. Payne, D. J., Gwynn, M. N., Holmes, D. J., Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery. 6, 29-40 (2007).
12. Parret, A. H. A., De Mot, R. Bacteria killing their own kind: novel bacteriocins of pseudomonas and other gamma-proteobacteria. Trends Microbiol. 10, 107-112 (2002).
13. Cascales, E. et al. Colicin biology. Microbiol. Mol. Bio. Rev. 71, 158-229 (2007).
14. Michel-Briand, Y., Baysse, C. The pyocins of Pseudomonas aeruginosa. Biochimie. 84, 499-510 (2002).
15. Fyfe, J. A. M., Harris, G., Govan, J. R. W. Revised pyocin typing ethod for Pseudomonas aeruginosa. J. Clin. Microbiol. 20, 47-50 (1984).
16. Elfarash, A., Wei, Q., Cornelis, P. The soluble pyocins S2 and S4 from Pseudomonas aeruginosa bind to the same FpvAI receptor. MicrobiologyOpen. 1, 268-275 (2012).
17. Elfarash, A. et al. Pore-forming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa. Microbiology-Uk. 160, 261-269 (2014).
18. Kleanthous, C. Swimming against the tide: progress and challenges in our understanding of colicin translocation. Nature Reviews Microbiology. 8, 843-848 (2010).
19. Ferguson, A. D., Deisenhofer, J. TonB-dependent receptors-structural perspectives. Biochim. Biophys. Acta. 1565, 318-332 (2002).
20. Housden, N. G. et al., Intrinsically Disordered Protein Threads Through the Bacterial Outer-Membrane Porin OmpF. Science. 340, 1570-1574 (2013).
21. Baysse, C. et al. Uptake of pyocin S3 occurs through the outer membrane ferripyoverdine type II receptor of Pseudomonas aeruginosa. J. Bacteriol. 181, 3849-3851 (1999).
22. McCaughey, L. C. et al. Lectin-like bacteriocins from Pseudomonas spp. utilise D-rhamnose containing lipopolysaccharide as a cellular receptor. PLoS. Pathog. 10, e1003898 (2014).
23. Weisner, A. M., Chart, H., Bush, A., Davies, J. C., Pitt, T. L. Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis. J. Med. Microbiol. 56, 670-674 (2007).
24. Lam, M. Y. C. et al. Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J. Clin. Microbiol. 27, 962-967 (1989).
25. Dingemans, J., Ghequire, M. G., Craggs, M., De Mot, R., Cornelis, P. Identification and functional analysis of a bacteriocin, pyocin S6, with ribonuclease activity from a Pseudomonas aeruginosa cystic fibrosis clinical isolate. MicrobiologyOpen (2016).
26. Barreteau, H. et al. Functional and structural characterization of PaeM, a colicin M-like bacteriocin produced by Pseudomonas aeruginosa. J. Biol. Chem. 287, 37395-37405 (2012).
27. Smith, K. et al. Activity of Pyocin S2 against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 56, 1599-1601 (2012).
28. Gillor, O., Kirkup, B. C., Riley, M. A. Colicins and microcins: The next generation antimicrobials. Advances in Applied Microbiology. 54, 129-146 (2004).
29. Joerger, R. D. Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. Poult Sci. 82, 640-647 (2003).
30. Gillor, O., Ghazaryan, L. Recent Advances in Bacteriocin Application as Antimicrobials. Recent Patents on Anti-Infective Drug Discovery. 2, 115-122 (2007).
31. Gupta, S., Bram, E. E., Weiss, R. Genetically programmable pathogen sense and destroy. ACS. Syn. Bio. 2, 715-723 (2013).
32. Carroll, K. C., Bartlett, J. G. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65, 501-521 (2011).
33. Gorkiewicz, G. Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. Int. J. Antimicrob. Agents. 33, 37-41 (2009).
34. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490, 55-60 (2012).
35. Manichanh, C., Borruel, N., Casellas, F., Guarner, F. The gut microbiota in IBD. Nature Rev. 9, 599-608 (2012).
36. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 482, 167-179 (2012).
37. Scher, J. U., Abramson, S. B., The microbiome and rheumatoid arthritis. Nature Rev. 7, 569-578 (2011).
38. Hao, Y., King, J. D., Huszczynski, S., Kocincova, D., Lam, J. S. Five new genes are important for common polysaccharide antigen biosynthesis in Pseudomonas aeruginosa. MBio. 4 (2013).
39. Dingemans, J. et al. The deletion of TonB-dependent receptor genes is part of the genome reduction process that occurs during adaptation of Pseudomonas aeruginosa to the cystic fibrosis lung. Pathog. Dis. 71, 26-38 (2014).
40. Haas, B., Kraut, J., Marks, J., Zanker, S. C., Castignetti, D. Siderophore presence in sputa of cystic-fibrosis patients. Infect. Immun. 59, 3997-4000 (1991).
41. Martin, L. W., Reid, D. W., Sharples, K. J., Lamont, I. L. Pseudomonas siderophores in the sputum of patients with cystic fibrosis. Biomaterials. 24, 1059-1067 (2011).